Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to ...

Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...

She emphasized the positive results of the HELIOS-B Phase 3 study, regulatory filings for vutrisiran in ATTR cardiomyopathy, and the company's transition to profitability with $95 million in non-GAAP ...

Nucresiran and Vutrisiran Advancements Demonstrate Durable Leadership in TTR Alnylam scientists will provide an update on the TRITON Phase 3 program for its next-generation transthyretin (TTR ...

We expect 2025 will represent an important inflection point for our TTR franchise, with the potential launch of vutrisiran in ATTR-CM delivering significant topline growth as reflected in our net ...

Amvuttra (vutrisiran) is a prescription drug that’s used to treat nerve damage related to a rare genetic condition. Amvuttra is given as an injection under your skin by a healthcare professional.

Alnylam Pharmaceuticals Inc.’s stock jumped nearly 40% premarket on Monday after the company released results of a late-stage trial for a heart drug that analysts see competing with a key Pfizer ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2024 and ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York City and will also webcast the event. The Company plans to showcase its R&D ...